SynBiotic

Management of Hempro International has announced it will file an application with the Münster district court to open preliminary insolvency proceedings. The causes are a marked drop in demand and sales since March 2026 due to worsening economic conditions following geopolitical events. SYNBIOTIC SE is reconsidering the operational development of its subsidiaries as part of restructuring measures and will no longer continue financial support for Hempro; potential impacts on the balance sheet and results are being reviewed. » Więcej na finanzen.net

The SynBiotic share lost 14.4% in Xetra trading and fell a further almost 20% in after-hours trading. The trigger was the official initiation of a US reclassification of cannabis intended to make medical use easier but not to provide nationwide legalization for recreational purposes. Ahead of this, the stock had already benefited from speculation about a loosening of US rules. » Więcej na finanzen.net

Synbiotic shares rose by more than 100% since Friday and continued on Wednesday with a gain of over 12% to 3.55 euros; intraday they reached up to 3.78 euros. Earlier in the week the papers had already climbed by as much as 42% after they had marked a record low near 1.50 euros last week. Analyst Harald Hof cited several positive triggers: two smaller capital increases, the insolvency of a non-core subsidiary, sector tailwinds and the entry of the hemp equity fund Cansoul as a new anchor investor in a cash capital increase. » Więcej na de.investing.com

SYNBIOTIC SE is using authorized capital to increase share capital by up to EUR 200,000 through the issuance of up to 200,000 new registered shares at a placement price of EUR 1.70 per share, with statutory subscription rights excluded. The new shares will be entitled to profits from 1 January 2024; Small & Mid Cap Investmentbank AG has been appointed to handle the placement. The net proceeds from the issuance are intended to support the company's growth. » Więcej na finanzen.net

Bushdoctor GmbH has applied to the Landesgericht Wiener Neustadt to open insolvency proceedings. As part of the restructuring, SYNBIOTIC suspended financial support for the subsidiary, which led to the filing. The announcement confirms that the operational development of the subsidiaries is being reviewed as part of the group restructuring. » Więcej na finanzen.net